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Purpose: Treatment withhematopoietic growth factors increases the percentage
ofhematopoietic progenitor cells in cell cycle. Following withdrawal ofcertain
growth factors, preclinical data suggest that there is a transient fall in the per-
centage ofprogenitor cells in cycle below the baseline, thus providing a window
to administer chemotherapy with reduced risk ofmyelotoxicity.
Patients and Methods: Patients with histologically confirmed, previously
untreated neoplasia, were treated with pIXY321 by subcutaneous injection at a
dose of 375 pg/m2 twice daily (total dose 750 Vg/m2/day) for seven days (days
-8 to -2), followed by a two-day rest (days -1 to 0). Patients received ICE (ifos-
famide, carboplatin and etoposide) on days 1 to 3. On day 4, pIXY321 was
resumed until hematologic recovery. Peripheral blood was collected on days -8,
-2, - 1, 1, and cell cycle distribution was determined using flow cytometry.
Results: Twenty patients were treated in this study and received a total of 54
cycles. Partial responses were observed in three of 13 patients with non-small
cell lung cancer (23 percent) and two of five patients with small cell lung can-
cer (40 percent). Six of 15 patients had an increased number ofcells in S+G /M
on day 1 ofICE following seven days ofpIXY321 and two days off (daysI to
0). The average increase was 63 percent (range 6-253). Seven patients had a
decreased number of cells in S+G /M The average decrease was 55 percent
(range 6.3-78). There were nosignificant differences among the fifteen patients
with regards to the observed toxicity ofthe chemotherapy.
Discussion: pIXY321 in this schedule did not consistently decrease the per-
centage of cycling progenitor cells in the peripheral blood. Future studies
should define whether other growth factors and/or schedules can synchronize
progenitor cell cycling and protect the marrow compartment from cycle specif-
ic chemotherapy.
INTRODUCTION
Cancer cell resistance to DNA damaging agents can be overcome by increasing the
dose intensity [1]. This observation has provided the rationale for the use of high dose
chemotherapy combined with growth factors, with or without autologous blood progeni-
tor cell rescue. Studies to date have shown that colony stimulating factors (CSFs)e
decrease the duration of myelosuppression and its associated morbidity [2, 3]. CSFs
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reduce the duration of neutropenia both by increasing the percentage of bone marrow
progenitor cells in cell cycle and by reducing the duration ofthe cell cycle. These growth
factors may have other effects on progenitor cell cycle kinetics, which could be exploited
to furtherreduce the degree ofmyelosuppression.Aglietta et al. noted that following com-
pletion of a three-day course of GM (granulocyte-macrophage)-CSF, the percentage of
bone marrow CFU-GM in S phase was significantly decreased below baseline within 24-
72 hours [4]. In a larger group of patients, Vadhan-Raj, Broxmeyer and colleagues con-
firmed these findings for GM-CSF and reported similar results with pIXY321, but not
with G-CSF [5-7]. These observations suggestedthat apriming schedule ofcertain growth
factors, coupled with the appropriate rest period before the administration of chemother-
apy, might reduce the percentage of marrow progenitor cells in cycle at the time the
chemotherapy is given and thus render the bone marrow less susceptible to chemotherapy
induced toxicity.
pIXY 321 is a recombinant protein that contains both IL-3 and GM-CSF domains [5,
8-10]. pIXY 321 producedsignificantly enhancedbiological effect in vitro on bothmyelo-
and thrombopoiesis, perhaps by multiple cross linking ofGM-CSF, IL-3 and dual recep-
tors [11, 12]. In clinical trials, pIXY 321 has been well tolerated with the most common
reported side-effectbeingerythema at the injection site andmild constitutional symptoms.
There appears to be a dose response effect at doses less than 1000Vg/m2/day [13]. Some
studies have shown abiological effect at a dose of 125 ,ug/m2/day, though in others a dose
of 500-750 ,ug/m2/day was necessary. The optimal biologic dose appears to be 375
pg/m2/day administered twice daily [13].
The combination ofthe DNA damaging agents ifosfamide, etoposide and a platinum
analog ("ICE") has demonstrated significant activity in lung cancer, germ cell tumors,
lymphomas and pediatric malignancies [14-20]. The major dose limiting toxicity of this
drug combination is myelosuppression, and significant dose escalation is feasible with the
use of bone marrow rescue or the addition of cytokines. For example, Tepler and col-
leagues found that a 25 percent increase in the dose intensity of carboplatin was feasible
when G-CSF was incorporated into the ICE regimen [19]. Furthermore, they reported that
when IL-3 was given in combination with G-CSF following this chemotherapy regimen,
the degree and duration of the myelosuppression was further reduced, suggesting that
there was synergy between G- or GM-CSF and IL-3.
Based on these data, we designed a study to measure the effects of a priming sched-
ule of pIXY321 on hematopoietic progenitor cell kinetics and assess whether priming
reduced the myelotoxicity anticipated with ICE chemotherapy.
PATIENTS AND METHODS
Eligibility
Patients with biopsy-proven, previously untreated solid tumors were eligible to par-
ticipate in this study. All patients were at or over 18 years of age, were not pregnant, had
an ECOG performance status <2, had adequate bone marrow function (defined as an
absolute neutrophil count >150041, and platelets >100,000/41), had adequate hepatic and
renal function (defined as a total bilirubin <1.5 mg/dl and a creatine clearance >60
ml/min) and measurable or evaluable disease. Patients excluded from enrollment includ-
ed those with a serious intercurrent medical illness, a priordiagnosis ofan invasive malig-
nancy (unless potentially curative treatment had been rendered and the disease-free inter-
val exceeded five years), patients with an active infection and patients with an anticipated
life expectancy of <2 months. Informed, written consent was obtained according to
Federal and Institutional guidelines.
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Dosages and drug administration
The pIXY321 was administered at a dose of 375 pg/m2 given subcutaneously twice
daily. The priming dose was delivered over seven days followed by a two-day rest before
the start ofthe chemotherapy. The pIXY321 was resumed at the same dose 24 hours after
the completion of chemotherapy (day 4) and was continued for 10 consecutive days or
until the WBC exceeded 15,000/p1 and the platelet count exceeded 100,0004i1.
Premedication for the chemotherapy consisted of20 mg ofondansetron or 0.1 mg/kg
of granisetron admixed with 10 mg of dexamethasone. The antiemetics were repeated
every eight to 12 hours as needed. Mesna at a dose of400 mg/M2 was infusedjust before
and then four, eight and 12 hours after the ifosfamide. The final two doses ofmesna were
sometimes given orally by diluting 800 mg/m2/dose of mesna in juice. Ifosfamide at a
dose of 2 gmlm2/d, and etoposide at a dose of 75 mg/m2/d, were given intravenously on
days 1 to 3 of each chemotherapy cycle. Carboplatin was administered at a dose of 400
mg/M2 on day 1 only ofeach cycle.
Chemotherapy was repeated every three weeks provided that there was hematologic
recovery (absolute neutrophil count >I500/pl and platelet >100,0004s1), complete resolu-
tion of mucositis and diarrhea, no evidence ofgross hematuria, and no other serious non-
hematologic toxicity.
The doses of all chemotherapy drugs were calculated according to the patient's actu-
al body weight, unless the body weight was more than 30 percent of the ideal weight. In
this situation, the ideal weight plus 30 percent was used to calculate doses. Dose reduc-
tion of 25 percent was permitted on subsequent chemotherapy cycles for grade 3 non-
hematologic toxicities, neutropenic fever with documented infection and a nadir platelet
count of<20,000/4t.
pIXY321 was supplied by the Immunex Corp (Seattle, WA) in 1.5 mg vials and was
reconstituted in 1 ml of bacteriostatic water. For some patients who experienced injection
site reactions, 1 mg of hydrocortisone sodium phosphate was injected into the pIXY321
vial before reconstitution.
On-study examinations and criteriafor assessment ofresponse and toxicity
A history including assessment ofperformance status, physical examination, a com-
plete blood count, electrolytes, BUN, creatinine, creatinine clearance, liver function tests
(aspartate aminotransferase, lactate dehydrogenase, total and direct bilirubin, alkaline
phosphatase), serum calcium and phosphate, total protein, albumin, prothrombin time, uri-
nalysis, pregnancy test (if indicated), chest radiograph and computed tomography scans
(if appropriate for staging the disease) were obtained prior to the start of treatment. A
physical examination and toxicity assessment were repeated weekly. Toxicity was graded
according to the National Cancer Institute common toxicity criteria. A complete blood
count and differential were obtained every two to three days while the patients were
receiving the pIXY321. The complete blood count and a chemistry profile was repeated
before every treatment cycle. Formal tumor measurements were obtained after every two
cycles of chemotherapy. Response duration was measured from the time of first docu-
mented response until progression. Survival was measured from the time ofentry on study
and estimated using the Kaplan-Meier method.
Analysis ofhematopoietic progenitor cell kinetics
On days -8 and -2 (the start and completion ofthe priming schedule ofpIXY321) and
day 1 ofchemotherapy during first and second cycles, 15 ml ofblood was obtained in anti-
coagulated tubes. Blood samples from patients treated at the Cancer Institute of New
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Jersey and at affiliated hospitals were shipped by overnight courier mail. Mononuclear
cells were isolated from the blood samples by centrifugation through a ficoll-Hypaque
density gradient. The mononuclear cells were washed, treated with RNase A, incubated
with a fluorocein-conjugated anti-CD34 monoclonal antibody and then stained with pro-
pidium iodide. The samples were analyzed in a flow cytometer, and the cell cycle distrib-
ution in the CD34 cell population was determined.
RESULTS
Twenty patients were entered into the study and received a total of 54 cycles (Table
1). Fourpatients experienced allergic reactions frompIXY321 and were removedfromthe
study prior to the administration of chemotherapy. An additional two patients withdrew
following the first cycle ofchemotherapy due to unacceptable side effects (1) or personal
reasons (1). These two patients were considered evaluable for both toxicity and response.
Response and survival
Among the 11 patients with non-small cell lung cancer, one patient had a partial
response, which lasted six months. Six patients had stable disease lasting five to seven
months. Among the four evaluable patients with small cell lung cancer, there were two
partial responses lasting five months each. One patient with poorly-differentiated carcino-
ma had stable disease lasting 11 months. The median survival for the 20 patients was 15
months. Seventy-one percent of the patients were alive at one year. No difference in sur-
vival was noted between responders and non-responders.
Hematologic toxicity
Neutropenia was the most prominent toxicity. Severe (grade 3-4) neutropenia was
noted during the first cycle in 42 percent ofthe patients, and four patients required hospi-
talization forneutropenic fever. Myelosuppression during subsequent treatmentcycles was
common. Dose modifications were required in 30 percent of the patients by cycle 3, 63
percent of the patients during cycle 4 and in all three of the patients who received five or
Table 1. Patient characteristics.
Patients 20
Sex
Female 11
Male 9
Age, years
Median 51.5
Range 33-68
ECOG performance status
0 13
1 6
2 1
Tumor histology/stage
Non-small-cell lung cancer
Stage III 2
Stage IV 11
Small-cell lung cancer
Extensive disease 4
Local disease 1
PDC (Unknown primary site) 2
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Table 2. Hematologic toxicities.
No. of Patients Patients transfused Patients transfused
patients dose modified with platelets with redblood cells
Cy treated no. (percent) no. (percent) no. (percent)
1 16 0 (0) 2 (13) 0 (0)
2 15 0(0) 2(13) 1(7)
3 10 3 (30) 5 (50) 4 (40)
4 8 5 (63) 0 (0) 2 (25)
5 3 3(100) 1 (33) 1 (33)
6 2 2 (100) 0 (0) 0 (0)
more cycles, indicating that the myelosuppression was cumulative. Treatment was discon-
tinued in one patient due to prolonged neutropenia following the fourth cycle of therapy.
Thrombocytopenia occurred frequently, and platelet transfusions were required in 19 per-
cent of the treatment cycles. Severe anemia occurred in 7 percent of the patients during
cycle 2, and 30 percent ofthe patients in cycle 3, and red blood cell transfusions were fre-
quently required (Table 2).
Non-hematologic toxicities
The most common non-hematological toxicities were mild fatigue and weight loss,
which were observed in 11 of 19 patients. Two patients developed mental status changes
during chemotherapy, which were attributed to the ifosfamide, and the patients had
chemotherapy discontinued after three cycles and two cycles, respectively.
Gastrointestinal side effects were uncommon, and consisted of mild stomatitis (1) and
diarrhea (2).
Local erythema and edema at the site of the pIXY injection was seen in seven
patients. Four of these patients experienced grade 2 erythema/edema at the site of injec-
tion, and an additional patient experienced grade 2 nausea/vomiting after the pIXY321
was administered. In two patients, hydrocortisone was mixed with the pIXY321 before
injection, and this reduced the severity ofthe local irritation. In an additional fourpatients,
however, allergic reactions were severe and precluded further participation in the study.
Three of these patients developed symptoms following the first or second injection of
pIXY321 consisting of sneezing, tongue swelling, difficulty swallowing, facial flushing,
drooling, chest pressure and dyspnea. The fourth patient experienced respiratory distress
and flushing following the first cycle oftherapy.
Three thrombotic events occurred in patients in this study. One patient experienced a
myocardial infarction and cardiac arrest after the second cycle of chemotherapy. This
patient had no prior anginal syndrome and had ahemoglobin of8.9 g/dl at the time ofthe
infarct. Two patients had documented deep venous thromboses. All three ofthese patients
had carcinoma of the lung and may have had activation of coagulation pathways prior to
the initiation of therapy.
Progenitor cell cycle kinetics
In five patients, there were insufficient numbers of progenitor cells detected in the
peripheral blood to determine cell cycle distribution at baseline. In the fifteen patients in
whom flow cytometric data are available, the average percentage of peripheral cells in
S+G2/M was 9.6 percent. As shown in Figure 1, six patients had an increased percentage
of cells in S+G2/M on day 1 of ICE following seven days ofpIXY321 and two days off
(days -8 to 1). The average increase was 63 percent (range 6-253 percent). Seven patients
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Figure 1. Cell cycle kinetics in peripheral CD34+ progenitor cells. Peripheral blood was sam-
pled and cell cycle distribution analyzed during priming with pIXY321 as described in the Methods.
Each line represents data from an individual patient.
Table 3. Bone marrow progenitor cell kinetics following growth factor prmning.
Percent progenitors in S phase
Priming schedulea Pts End 2-4d
(CSF/days on/days off) Assay methodb (no.) Baseline Prime off Ref.
GM-CSF/3d/l-4 d [3H]Tdr Suicide 7 19 32 13d [4]
GM-CSF/14d/1-4d [3H]Tdr Suicide 14 18 55 8 [7]
GM-CSF/lOd/1-7d BUDR LI 5 4.7 8.2 7.4 [32]
GM-CSF/7d/1-4d BUDR LI 9 12.8 20.2 5.2 [25]
G-CSF/7d/1-4d BUDR LI 9 4.9 19.6 20 [25]
G-CSF/8d/2-4d [3H]Tdr Suicide 6 27 51 43 [61
pIXY321/14d/2d [3H]Tdr Suicide 15 36 62 15d [5]
pIXY321/7d/2d PI stain CD34+ PB 17 10.4 9.4 8.1 e
CSF = colony stimulating factor; PI = propidium iodide; PB = peripheral blood; BUDR LI = bro-
modeoxyuridine labeling index.
aDays on = no. ofdays priming growth factor given; days off = no. ofdays before start of chemo.
bMaffow was obtained at baseline, at the end of priming schedule, and then two to four days after
the last dose ofgrowth factor
CDNA synthesis was determined by a [3H]Tdr suicide assay in CFU-GM or by in vivo
bromodeoxyuridine labeling index.
dp <.05 compared with data from baseline.
e'This study.
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had a decreased percentage of cells in S+G2/M. The average decrease was 55 percent
(range 6.3-78 percent). Nine patients also had flow cytometric data available on day -2 (at
the end ofpriming). In five ofthese patients, the percentage ofperipheral cells in S+G2/M
was decreased on day 1 of ICE compared to day -2. The mean decrease was 21 percent,
and the median was 6.1 percent. In the fourpatients in whom there was an increase in the
percentage of peripheral cells in S+G2/M on day 1 of ICE, the average increase was 47
percent, with the median being 52 percent. No correlation between number or percentage
ofprogenitor cells in S phase on day 1, and subsequent myelosuppression or transfusion
requirement was identified.
DISCUSSION
Although most clinical trials have reported that pIXY321 is well tolerated, the fre-
quency of certain non-hematologic toxicities in this study was notable. Four patients (20
percent) had allergic reactions severe enough to preclude continued treatment on the
study. This is higher than the incidence ofsevere allergic reactions reported in other stud-
ies ofpIXY321 and much higher than the incidence observed with either GM-CSF or G-
CSF. Three of the 20 patients experienced thrombotic events. Proposed mechanisms by
which these cytokines may contribute to hypercoagulability include induction ofadhesion
molecule expression on neutrophils and enhancement ofplatelet aggregation [21-23]. In a
recent meta-analysis, the incidence of thrombotic events among patients receiving GM-
CSF was 6.6 percent compared with 3.6 percent in controls, with an odds ratio of 1.67
(p >.05) [24]. An unexpectedly high incidence of thrombotic events has not been previ-
ously reported with pIXY321 and may reflect selection in this small patient cohort. If
pIXY321 is further developed, however, additional investigation into its thrombogenic
potential should be performed.
Some previous studies have suggested thatcertain cytokines givenprior to the admin-
istration ofchemotherapy decrease the percentage ofprogenitor cells in cycle, thus mak-
ing the bone marrow protentially more resistant to the myelosuppressive effects of
chemotherapy (Table 3). For example, an Italian group found differences in the kinetic
effects induced by GM- and G-CSF [25]. They reported that the bromodeoxyuridine
(BUDR) labeling index in CD34+ marrow cells fell significantly below baseline two days
after stopping GM-CSF but was still elevated two to four days after stopping G-CSF.
Differences in these observed kinetic effects may be related to the population of cells
expanded by a particular growth factor. Expansion of more primitive cell compartments
might be necessary to affect feedback loops regulating hematopoiesis [26] and may con-
tribute to the variable results summarized in Table 4. In addition to the growth factor and
the schedule, the results observed in Table 4 may also be related to biologic differences
between CD34+ progenitor cells obtained in the peripheral blood and CD34+ progenitor
cells residing in the marrow [27]. Although Paccagnella et al. reported that priming pro-
duced comparable results on the kinetics of these two cell populations [28], in a limited
numberofsamples using different assay techniques we foundpooragreementbetween the
priming effects on marrow and peripheral blood progenitor cells. Future studies should
analyze marrow samples until effective priming schedules are defined and subsequently
correlated with kinetics in peripheral progenitor cells.
Evaluation ofapriming schedule ofgrowth factoradministration as a means ofreduc-
ing myelotoxicity has been clinically tested in a limited number ofpatients. Aglietta et al.
demonstrated reduced myelotoxicity in a small group ofpatients randomized to treatment
with a priming schedule of GM-CSF [29]. In this study, none of the patients received
growth factor support following chemotherapy. Janick et al. treated 24 evaluable patients
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Table 4. Impact ofgrowth factor priming on subsequent myelosuppresion.
Priming schedule Chemo Patients
CSF/days on/days off regimen (no.)b Results Ref.
GM-CSF/lOd/7d P/E/E 5/42 Compared to patients treated
with only post-chemo GM-CSF,
no further reduction in
myelotoxicity noted in patients
receiving priming.
GM-CSF/1 Id/3d C/E/Ctx 18 Compared to patients treated
only with GM-CSF, less
myelotoxicity ifPBSC infused.
+/- GM-CSF/3d/4d
(Randomized)
+/- GM-CSF/5d/2d
(Randomized)
CEF 6/12
VP-16, p.o. 9/27
21d schedule
No post-chemo GM-CSF
given. Significantly higher
ANC and less treatment delays
in primed group.
Priming increased
myelosuppresion (not significant)
c/w no GM-CSF support.
+/- GM-CSF/5d/3d
(Randomized, all patients
post-chemo G-CSF)
+/- GM-CSF/5d/ld
(Randomized)
HDCEP 36/72 Priming reduced PBSC yield
without reducing
myelotoxicity
Topotecan 14/27 Priming reduced gr 4
neutropenia in cycles 1 and 2.
pIXY321/14d/7d CyADIC 23 At low doses ofpIXY321
(25-250 pg/m2/d), no difference
between prime only (cycle 1)
vs. post-chemo pIXY (cycle 2).
At doses of 500-1000 ,ug/m2/d,
reduced myelotoxicity in cycle 2.
Melphalan 4/16 No difference in
myelosuppression c/w patients
treated with prime.
Topotecan/
CDDP
5/35 No difference in
myelosuppression c/w 6
patients treated at same chemo
doses without prime.
[35]
[36]
CEF/CMF = cyclophosphamide, epirubicin, 5-fluorouacil alternating with cyclophosphamide,
methotrexate, 5-fluorouacil; C/E/Ctx = carboplatin, etoposide, cyclophosphamide; P/E/E = cis-
platin, epirubicin, etoposide; CyADIC = cyclophosphamide, doxorubicin, dacarbazine; HDCE =
high-dose cyclophosphamide, etoposide, cisplatin; PBSC = peripheral blood stem cells; CDD = cis-
platin.
aDays on = no. ofdays priming growth factor given; days off = no. ofdays before start of chemo.
bPatients receiving priming schedule/total patients treated in study.
[28]
[33]
[29]
[34]
[311
[30]
[13]
G-CSF/8d/2d
G-CSF/5d/2d
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with topotecan followed by seven days of GM-CSF [30]. Half of the patients were ran-
domized to also receive a five-day priming course of GM-CSF, which was completed 24
hours before the start of chemotherapy. A significant decrease in the number of patients
experiencing grade 4 neutropenia (27 percent vs. 77 percent, p = .02) was noted in the
patients treated with the priming schedule. In contrast, Schwartzberg et al. found no
advantage with a five-day GM-CSF priming schedule when used in combination with a
dose-intensive regimen containing cyclophosphamide, cisplatin, and etoposide [31].
The clinical efficacy observed by Janik et al. may be in part related to the use of a
cycle-specific chemotherapy regimen. In a murine model, de Haan et al. recently demon-
strated that the combination of stem cell factor and IL-I1 given for seven days followed
by a one day rest before cycle-specific chemotherapy (5-fluorouracil) reduced the per-
centage ofprogenitorcells in cycle atthe time ofchemotherapy, andprotected the animals
from treatment-related toxicity [26]. In contrast to alkylating drugs, the cytotoxicity ofthe
camptothecins is highly dependent on cells transversing the cell cycle. Since the dose lim-
iting toxicity ofthis class ofagents is myelosuppression, they are uniquely suited foreval-
uation ofpriming schedules designed to reduce the percentage ofmarrow progenitor cells
in cycle. Therefore, future studies that test priming schedules of cytokines such as GM-
CSF should be designed utilizing cycle-specific agents such as the camptothecins.
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